Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks

References

• Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801–1809.
   PubMed Web of Science ®Google Scholar
• Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost. 2008;34:128–142.
   PubMed Web of Science ®Google Scholar
• Pavlova A, Oldenburg J. Defining severity of hemophilia: more than factor levels. Semin Thromb Hemost. 2013;39:702–710.
   PubMed Web of Science ®Google Scholar
• White GCII, Rosendaal F, Aledort LM, et al. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on Factor VIII and Factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
   PubMed Web of Science ®Google Scholar
• Pollmann H, Richter H, Ringkamp H, et al. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr. 1999;158:S166–70.
   PubMed Web of Science ®Google Scholar
• Fischer K, Van Der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002;99:2337–2341.
   PubMed Web of Science ®Google Scholar
• Pergantou H, Matsinos G, Papadopoulos A, et al. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilicarthropathy in children. Haemophilia. 2006;12:241–247.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-47.
   PubMed Web of Science ®Google Scholar
• Ahlberg A. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthop Scand. 1965;77:5–99.
   Google Scholar
• Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia A. Bibl Haematol. 1970;34:111–124.
   PubMedGoogle Scholar
• Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol. 1969;41:206–214.
   PubMed Web of Science ®Google Scholar
• Lofqvist T, Nilsson IM, Berntorp E, et al. Haemophilia prophylaxis in young patients – a long-term follow-up. J Intern Med. 1997;241:395–400.
   PubMed Web of Science ®Google Scholar
• Fischer K, Van Der Bom JG, Mauser-Bunschoten EP, et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia. 2001;7:446–452.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, Von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).. J Thromb Haemost. 2011;9:700–710.
   PubMed Web of Science ®Google Scholar
• Clausen N, Petrini P, Claeyssens-Donadel S, et al. PedNet, Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia. 2014;20:747–755.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11:1119–1127.
   PubMed Web of Science ®Google Scholar
• Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol. 2012;88:329–335.
   PubMed Web of Science ®Google Scholar
• Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391–399.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935–1939.
   PubMed Web of Science ®Google Scholar
• Fisher K, Astermark J, Van Der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate dose regimen to a high dose regimen. Haemophilia. 2002;8:753–760.
   PubMed Web of Science ®Google Scholar
• Feldman BM, Pai M, Rivard GE, et al. Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group, et al. Tailored prophylaxis in severe haemophilia A: interim results from the first 5 year of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2006;4:1228–1236.
   PubMed Web of Science ®Google Scholar
• Fischer K, Ljung R. Primary prophylaxis in haemophilia care: guideline update 2016. Blood Cells Mol Dis. 2017;67:81–85.
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. rAHF–PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7:413–420.
   PubMed Web of Science ®Google Scholar
• Jimenez-Yuste V, Auerswald G, Benson G, et al. Achieving and maintaining an optimal through level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus. 2014;12:314–319.
   PubMed Web of Science ®Google Scholar
• Skinner MW. WFH: Closing the global gap – achieving optimal care. Haemophilia. 2012;18:S1–S12.
   PubMed Web of Science ®Google Scholar
• Liesner RJ, Vora AJ, Hann IM, et al. Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol. 1995;91:203–220.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Al-Musa A, Stain AM, et al. Central venous access devices in children with haemophilia. Blood Coag Fibrin. 1996;7:S39–S44.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Gringeri A, Muça-Perja M, et al. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol. 1998;102:1224–1228.
   PubMed Web of Science ®Google Scholar
• Langley AR, Stain AM, Chan A, et al. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS). Haemophilia. 2015;21:469–476.
   PubMed Web of Science ®Google Scholar
• Khair K, Ranta S, Thomas A, et al. PedNet study group. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia. 2017;23:e276–81.
   PubMed Web of Science ®Google Scholar
• Hothi DK, Kelsall W, Baglin T, et al. Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters. Haemophilia. 2001;7:507–510.
   PubMed Web of Science ®Google Scholar
• Journeycake JM, Quinn CT, Miller KL, et al. Catheter-related deep venous thrombosis in children with hemophilia. Blood. 2001;98:1727–1731.
   PubMed Web of Science ®Google Scholar
• Ettingshausen CE, Kurnik K, Schobess R, et al. Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease. Blood. 2002;99:1499–1500.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Gringeri A, Berardinelli L, et al. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol. 2003;123:502–506.
   PubMed Web of Science ®Google Scholar
• Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2011;7:392–396.
   Google Scholar
• Schrijvers LH, Uitslager N, Schuurmans MJ, et al. Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia. 2013;19:355–361.
   PubMed Web of Science ®Google Scholar
• Meichenbaum D, Turk DC. Facilitating treatment adherence. New York: Plenum Press; 1987.
   Google Scholar
• Duncan N, Kronenberger W, Roberson C, et al. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia. 2010;16:247–255.
   PubMed Web of Science ®Google Scholar
• Llewellyn CD, Miners AH, Lee CA, et al. The illness perceptions and treatment beliefs of individuals with severe haemophilia and their role in adherence to home treatment. Psycho Healh. 2003;18:185–200.
   Web of Science ®Google Scholar
• De Moerloose P, Urbancik W, Van Den Berg HM, et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14:931–938.
   PubMed Web of Science ®Google Scholar
• Ho S, Gue D, McIntosh K, et al. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia. Haemophilia. 2014;20:39–43.
   PubMed Web of Science ®Google Scholar
• Schrijvers LH, Kars MC, Beijlevelt Van Der Zande M, et al. Unravelling adherence to prophylaxis in haemophilia: a patients’ perspective. Haemophilia. 2015;21:612–621.
   PubMed Web of Science ®Google Scholar
• Verma SP, Dutta TK, Mahadevan S, et al. A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia – a success story from a resource limited country. Haemophilia. 2016;22:342–348.
   PubMed Web of Science ®Google Scholar
• Gouider E, Jouini L, Achour M, et al. Low dose prophylaxis in Tunisian children with haemophilia. Heamophilia. 2017;23:77–81.
   PubMed Web of Science ®Google Scholar
• Collins PW. Personalized prophylaxis in haemophilia patients. Haemophilia. 2012;18:S131–5.
   PubMed Web of Science ®Google Scholar
• Farrugia A, Noone D, Schlenkrich U, et al. Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics. J Blood Med. 2015;6:185–195.
   PubMed Web of Science ®Google Scholar
• Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13:606–612.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003;102:2358–2363.
   PubMed Web of Science ®Google Scholar
• Dolan G, Benson G, Duffy A, et al. Haemophilia B: where are we now and what does the future hold?. Blood Rev. 2018;32(1):52–60.
   PubMed Web of Science ®Google Scholar
• Astermark J, Altisent C, Batorova A, et al. European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16:747–766.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study. Br J Haematol. 2005;130:422–427.
   PubMed Web of Science ®Google Scholar
• Gouw SC, Van Der Bom JG, Van Den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648–4654.
   PubMed Web of Science ®Google Scholar
• Kurnik K, Auerswald G, Kreuz W. Inhibitors and prophylaxis in paediatrichaemophilia patients: focus on the German experience. Thromb Res. 2014;134:S27–32.
   PubMed Web of Science ®Google Scholar
• Gouw SC, Van Den Berg HM, Fischer K, et al. PedNet, Research Of Determinants of INhibitor development (RODIN) StudyGroup, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046–4055.
   PubMed Web of Science ®Google Scholar
• Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia. 2009;16:66–70.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016;374:2054–2064.
   PubMed Web of Science ®Google Scholar
• Young G, Shafer FE, Rojas P, et al. Single 270 micro kg(−1)-dose rFVIIa vs. Standard 90 micro kg(−1)-dose rFVIIa and aPCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14:287–294.
   PubMed Web of Science ®Google Scholar
• Astermark J, Donfield SM, DiMichele DM, et al. FENOC Study Group. A randomized comparison of bypassing agents in haemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546–551.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Austin SK, Kessler CM. ITI choice for the optimal management of inhibitor patients – from a clinical and farmacoeconomic perspective. Haemophilia. 2014;20:S17–26.
   PubMed Web of Science ®Google Scholar
• DiMichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia. 2009;15:320–328.
   PubMed Web of Science ®Google Scholar
• Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365:1684–1692.
   PubMed Web of Science ®Google Scholar
• Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20:65–72.
   PubMed Web of Science ®Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–1913.
   PubMed Web of Science ®Google Scholar
• Ljung R. Aspects of prophylactic treatment of hemophilia. Thromb J. 2016;14:S60–63.
   Web of Science ®Google Scholar
• Laffan M. New products for treatment of haemophilia. Br J Haematol. 2016;172:23–31 .
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Lai X, et al. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at a single- molecule level. Proc Natl Acad Sci USA. 2004;101:11076–11081.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317–325.
   PubMed Web of Science ®Google Scholar
• Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016;22:72–80.
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13:967–977.
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant fusion IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119:666–672.
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IXFc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323.
   PubMed Web of Science ®Google Scholar
• Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IXFc fusion protein in children with hemophilia B (Kids B-Long): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4:e75–e82.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Fisher K, Ragni M, et al. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IXFc fusion protein (rFIXFc)in subjects with hemophilia B. Thromb Haemost. 2017;117:508–518.
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015 27;126:1078–1085.
   PubMed Web of Science ®Google Scholar
• Reding MT, Ng HJ, Poulsen LH, et al. Safety and Efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017;15:411–419.
   PubMed Web of Science ®Google Scholar
• Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117:252–261.
   PubMed Web of Science ®Google Scholar
• Ostergaard H, Bjelke JR, Hansen L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated in native N-glycans in the activation peptide. Blood. 2011;118:2333–2341.
   PubMed Web of Science ®Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118:2695–2701.
   PubMed Web of Science ®Google Scholar
• Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm 4). Thromb Res. 2016;141:69–76.
   PubMed Web of Science ®Google Scholar
• Carcao M, Zak M, Karim FA, et al. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. J Thromb Haemost. 2016;14:1521–1529.
   PubMed Web of Science ®Google Scholar
• Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102:634–644.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120:2405–2411.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Lissitchkov T, Lubetsky A, et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia. 2015;21:784–790.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127:1761–1769.
   PubMed Web of Science ®Google Scholar
• Kenet G, Chambost H, Male C, et al. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children: results of a phase 3 trial. Thromb Haemost. 2016;116:659–688.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol. 2009;65:989–998.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of patient: implications for dosing in prophylaxis. Haemophilia. 2001;7:133–139.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Biguzzi E. Advances in the treatment of bleeding disorders. J Thromb Haemost. 2016;14:2095–2106 .
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–2053.
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in health subjects. Blood. 2016;127:1633–1641.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia with inhibitors. N Engl J Med. 2017;377:809–818 .
   PubMed Web of Science ®Google Scholar
• Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol. 2016;36:9–14.
   PubMed Web of Science ®Google Scholar
• Erhardtsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis. 1995;6:388–394.
   PubMed Web of Science ®Google Scholar
• Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood. 2008;111:672–679.
   PubMed Web of Science ®Google Scholar
• Maroney SA, Mast AE. New insights into the biology of tissue factor pathway inhibitor. J Thromb Haemost. 2015;13:S200–7.
   PubMed Web of Science ®Google Scholar
• Petersen LC. Hemostatic properties of a TFPI antibody. Thromb Res. 2012;129(Suppl2):44–45.
   Google Scholar
• Chowdary P, Lethagen S, Friederich U, et al. Safety and pharmacokinetics of anti-TFPIantibody (concizumab) in healthy volunteers and patients with hemophilia A: a randomized first human dose trial. J Thromb Haemost. 2015;13:743–754.
   PubMed Web of Science ®Google Scholar
• Gu J-M, Zhao X-Y, Schwarz T, et al. Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys. AAPS J. 2017;19:1186–1195.
   PubMed Web of Science ®Google Scholar
• Cardinal M, Kantaridis C, Zhu T et al. A first-in-human (FIH) study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-06741086, an anti-TFPI monoclonal antibody, following administration of single subcutaneous or intravenous doses in healthy adult male volunteers. ISTH Congress 2017 Jul 8- 13;Berlin, Germany
   Google Scholar
• Bolliger D, Szlam F, Suzuki N, et al. Heterozygous antithrombin deficiency improves in vivo haemostasis in FVIII-deficient mice. Thromb Haemost. 2010;103:1233–1238.
   PubMed Web of Science ®Google Scholar
• Ragni MV. Targeting antithrombin to treat hemophilia. N Engl J Med. 2015;373:389–391.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAitherapy. N Engl J Med. 2017;377:819–828.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Georgiev P, Mant T, et al. A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim weekly and monthly dosing results in patients with hemophilia A or B. Blood. 2015;126:551.
   Web of Science ®Google Scholar